Lower urinary tract symptom improvement after radical prostatectomy correlates with degree of prostatic inflammation

Urology

Volumn 83, Issue 1, 2014, Pages 186-190

  Burris, Michael B ^a   Cathro, Helen P ^a   Kowalik, Casey G ^b   Jensen, Drew ^a   Culp, Stephen H ^a   Steers, William D ^a   Krupski, Tracey L ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BODY MASS; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE WEIGHT; PROSTATECTOMY; PROSTATITIS;

AGED; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATITIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84891273740     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2013.07.080     Document Type: Article

References (26)

1. V. Kupelian, J.T. Wei, and M.P. O'Leary et al. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) survey Arch Intern Med 166 2006 2381 2387
2. F. Di Silverio, C. Bosman, and M. Salvatori et al. Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) Eur Urol 47 2005 72 78 [discussion: 78-79]
3. I. Ozdemir, O. Bozkurt, and O. Demir et al. Combination therapy with doxazosin and tenoxicam for the management of lower urinary tract symptoms Urology 74 2009 431 435
4. M. Gacci, L. Vignozzi, and A. Sebastianelli et al. Metabolic syndrome and lower urinary tract symptoms: the role of inflammation Prostate Cancer Prostatic Dis 16 2013 101 106
5. F. Di Silverio, V. Gentile, and A. De Matteis et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis Eur Urol 43 2003 164 175
6. J.C. Nickel, J. Downey, I. Young, and S. Boag Asymptomatic inflammation and/or infection in benign prostatic hyperplasia BJU Int 84 1999 976 981
7. R.E. Gerstenbluth, A.D. Seftel, and G.T. MacLennan et al. Distribution of chronic prostatitis in radical prostatectomy specimens with up-regulation of bcl-2 in areas of inflammation J Urol 167 2002 2267 2270
8. J.G. Masters, and M.L. Rice Improvement in urinary symptoms after radical prostatectomy: a prospective evaluation of flow rates and symptom scores BJU Int 91 2003 795 797
9. E.J. Schwartz, and H. Lepor Radical retropubic prostatectomy reduces symptom scores and improves quality of life in men with moderate and severe lower urinary tract symptoms J Urol 161 1999 1185 1188
10. M.J. Barry, F.J. Fowler Jr., and M.P. O'Leary et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association J Urol 148 1992 1549 1557 [discussion: 1564]
11. S.A. Kaplan, C.G. Roehrborn, and J.D. McConnell et al. Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial J Urol 180 2008 1030 1032 [discussion: 1032-1033]
12. J.D. McConnell, C.G. Roehrborn, and O.M. Bautista et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia N Engl J Med 349 2003 2387 2398
13. J.C. Nickel, C.G. Roehrborn, and M.P. O'Leary et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial Eur Urol 54 2008 1379 1384
14. J.H. Chung, J.H. Yu, and L.H. Sung et al. Effect of prostatitis on lower urinary tract symptoms: retrospective analysis of prostate biopsy tissue Korean J Urol 53 2012 109 113
15. J.A. Macoska Chemokines and BPH/LUTS Differentiation 82 2011 253 260
16. G. Theyer, G. Kramer, and I. Assmann et al. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia Lab Invest 66 1992 96 107
17. G. Steiner, A. Gessl, and G. Kramer et al. Phenotype and function of peripheral and prostatic lymphocytes in patients with benign prostatic hyperplasia J Urol 151 1994 480 484
18. G. Robert, A. Descazeaud, and N. Nicolaïew et al. Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis Prostate 69 2009 1774 1780
19. K.L. Lee, and D.M. Peehl Molecular and cellular pathogenesis of benign prostatic hyperplasia J Urol 172 5 Pt 1 2004 1784 1791
20. G. Kramer, D. Mitteregger, and M. Marberger Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 51 2007 1202 1216
21. A. Sciarra, F. Di Silverio, and S. Salciccia et al. Inflammation and chronic prostatic diseases: evidence for a link? Eur Urol 52 2007 964 972
22. S. Rohrmann, A.M. De Marzo, and E. Smit et al. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III) Prostate 62 2005 27 33
23. J.L. St Sauver, A.V. Sarma, and D.J. Jacobson et al. Associations between C-reactive protein and benign prostatic hyperplasia/lower urinary tract symptom outcomes in a population-based cohort Am J Epidemiol 169 2009 1281 1290
24. W.S. Choi, W.K. Lee, and S.H. Lee et al. Is high-sensitivity C-reactive protein associated with lower urinary tract symptoms in aging men? Results from the hallym aging study Korean J Urol 53 2012 335 341
25. M.A. Gates, S.A. Hall, and G.R. Chiu et al. Nonsteroidal antiinflammatory drug use and lower urinary tract symptoms: results from the Boston area community health survey Am J Epidemiol 173 2011 1022 1031
26. D. Altavilla, L. Minutoli, and F. Polito et al. Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia Br J Pharmacol 167 2012 95 108